Park Kyung Mi, Yang Eu Jeen, Lim Young Tak
Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Korea.
J Pediatr Hematol Oncol. 2017 Nov;39(8):e508-e511. doi: 10.1097/MPH.0000000000000841.
Intravenous immunoglobulin (IVIG) is a widely used agent as the first choice of treatment of immune thrombocytopenic purpura (ITP). IVIG has several side effects, but it is a relatively safe treatment. Life-threatening thrombosis has been reported in adults and rarely in children. We report a case of a 14-year-old boy with dural venous sinus thrombosis and pulmonary embolism after treatment with IVIG for ITP. The patient was treated with low-molecular-weight heparin followed by warfarin and the symptoms were recovered. If a patient with ITP shows mental change or respiratory difficulty, we should consider thrombosis as well as hemorrhage.
静脉注射免疫球蛋白（IVIG）是广泛应用的药物，作为免疫性血小板减少性紫癜（ITP）治疗的首选。IVIG有多种副作用，但它是一种相对安全的治疗方法。成人中曾报道有危及生命的血栓形成，儿童中则很少见。我们报告一例14岁男孩，在接受IVIG治疗ITP后发生硬脑膜静脉窦血栓形成和肺栓塞。该患者接受了低分子量肝素治疗，随后使用华法林，症状得以缓解。如果ITP患者出现精神改变或呼吸困难，我们应同时考虑血栓形成和出血。
